DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Sees Significant Decrease in Short Interest

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) was the recipient of a significant decline in short interest in December. As of December 31st, there was short interest totaling 4,093,770 shares, a decline of 22.8% from the December 15th total of 5,301,959 shares. Based on an average daily trading volume, of 379,867 shares, the days-to-cover ratio is presently 10.8 days. Approximately 8.5% of the shares of the stock are short sold. Approximately 8.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 379,867 shares, the days-to-cover ratio is presently 10.8 days.

Insiders Place Their Bets

In other DiaMedica Therapeutics news, major shareholder Jan Stahlberg acquired 240,352 shares of the company’s stock in a transaction that occurred on Wednesday, November 19th. The shares were purchased at an average price of $7.21 per share, with a total value of $1,732,937.92. Following the completion of the acquisition, the insider directly owned 8,375,092 shares of the company’s stock, valued at approximately $60,384,413.32. The trade was a 2.95% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders acquired a total of 1,061,277 shares of company stock worth $7,632,627 over the last quarter. Corporate insiders own 7.30% of the company’s stock.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. purchased a new position in DiaMedica Therapeutics during the third quarter worth approximately $27,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of DiaMedica Therapeutics in the 2nd quarter worth $29,000. Bank of America Corp DE raised its position in shares of DiaMedica Therapeutics by 3,710.3% in the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock worth $33,000 after buying an additional 8,274 shares during the period. JPMorgan Chase & Co. acquired a new position in DiaMedica Therapeutics in the second quarter valued at $49,000. Finally, Invesco Ltd. purchased a new position in shares of DiaMedica Therapeutics in the 2nd quarter worth about $54,000. 10.12% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of DiaMedica Therapeutics in a research note on Friday, November 14th. They set an “overweight” rating on the stock. TD Cowen assumed coverage on shares of DiaMedica Therapeutics in a research report on Thursday, October 30th. They set a “buy” rating on the stock. Lake Street Capital reaffirmed a “buy” rating on shares of DiaMedica Therapeutics in a report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, October 8th. Finally, Wall Street Zen cut shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $12.33.

DiaMedica Therapeutics Price Performance

DMAC traded down $0.21 during trading on Tuesday, hitting $7.36. The company’s stock had a trading volume of 288,340 shares, compared to its average volume of 239,987. DiaMedica Therapeutics has a twelve month low of $3.19 and a twelve month high of $10.42. The stock has a market cap of $383.36 million, a PE ratio of -10.39 and a beta of 1.15. The firm’s 50 day moving average price is $8.14 and its 200-day moving average price is $6.68.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its earnings results on Wednesday, November 12th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Equities analysts anticipate that DiaMedica Therapeutics will post -0.59 earnings per share for the current year.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.